Leman

Leman Biotech Co., Ltd. was founded in July 2021, focusing on the research, development, production, and commercialization of novel cancer immunotherapy drugs. Based on the innovative Meta10 immune-metabolic reprogramming technology, the company has established an intellectual property-owned immune-metabolic reprogramming biologics platform, a metabolism-enhanced immune cell therapy platform, and an AI computation-based super immune-metabolism modulator R&D platform. Leman has developed a distinctive product pipeline with significant differentiation, strong global competitiveness, and a well-structured iterative upgrade mechanism. The biologics have been proven to significantly enhance various immunotherapies, including immune cell therapy, immune checkpoint inhibitors, and immune agonists. The new metabolism-enhanced immune cell therapy technology has demonstrated remarkable therapeutic effects in multiple mouse solid tumor models, lung cancer metastasis models, and human tumor animal models, showing potential as an effective drug for curing solid tumors. Meanwhile, Leman has entered into an in-depth strategic partnership with XtalPi, an AI pharmaceutical company, to develop an AI computation-based super immune-metabolism modulator R&D platform.